In This Article:
Gilead Sciences Inc. GILD recently announced that the FDA has placed a partial clinical hold on studies evaluating the combination of magrolimab plus azacitidine.
Magrolimab is a potential, first-in-class investigational monoclonal antibody against CD47 and a macrophage checkpoint inhibitor.
The combination is being evaluated in various studies across a range of indications. The studies impacted by this partial clinical hold include phase III ENHANCE study in myelodysplastic syndrome (MDS), phase III ENHANCE-2 study in acute myeloid leukemia (AML), phase III ENHANCE-3 study in unfit AML, phase Ib study in MDS and phase II study in myeloid malignancies.
The hold was placed due to an apparent imbalance in investigator-reported suspected unexpected serious adverse reactions (SUSARs) between study arms.
Although there was no trend in the adverse reactions and a new safety signal was identified by Gilead, the partial clinical hold is being implemented across all ongoing magrolimab and azacitidine combination studies worldwide in the best interests of patients.
The company is collecting additional data and analyzing the same.
Screening and enrollment of new study participants will be paused in any study investigating the combination of magrolimab with azacitidine as a result of this hold. Other magrolimab studies or cohorts not studying the combination of magrolimab plus azacitidine will continue without any impact by the partial clinical hold.
Magrolimab was added to Gilead’s pipeline with the acquisition of Forty Seven, Inc in 2020 for approximately $4.9 billion.
The news of clinical hold was disappointing as the successful development of the candidate will propel Gilead’s efforts to build an oncology franchise.
Shares of GILD have gained 4.1% in the year against the industry’s 38.5% decline.
Image Source: Zacks Investment Research
The decline in its legacy HCV business and increasing competition in the HIV business propelled Gilead to diversify into the lucrative oncology space, which promises great potential despite fierce competition.
To that end, Gilead has made good progress of late. It recently exercised its options for three programs in the Arcus Biosciences, Inc. clinical-stage oncology portfolio.
Gilead announced it has entered into two clinical trial collaboration and supply agreements with pharma giant Merck MRK.
Gilead and Merck have collaborated to evaluate the combination of the former’s Trop-2 targeting antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) and the latter’s anti-PD-1 therapy Keytruda in first-line metastatic non-small cell lung cancer (NSCLC).